Thromb Haemost 1991; 65(03): 251-256
DOI: 10.1055/s-0038-1647660
Original Article
Schattauer GmbH Stuttgart

A Randomised Trial of Subcutaneous Low Molecular Weight Heparin (CY 216) Compared with lntravenous Unfractionated Heparin in the Treatment of Deep Vein Thrombosis

A Collaborative European Multicentre Study,
J Ninet
1  CHU Lyon E. Herriot
,
Ph Bachet
1  CHU Lyon E. Herriot
,
P Prandoni
2  CHU Padoue
,
A Ruol
2  CHU Padoue
,
M Vigo
2  CHU Padoue
,
A Barret
3  CHU Toulouse
,
O Mericq
3  CHU Toulouse
,
B Boneu
3  CHU Toulouse
,
G Janvier
4  CHU BordeauX
,
P Duroux
5  CHU paris-Clamart
,
Ph Girard
5  CHU paris-Clamart
,
M C Laprevote-Heully
6  CHU Nancy
,
P Sourou
7  CHU Nantes
,
D Robert
8  Lyon croix-Rousse
,
M Chagny
8  Lyon croix-Rousse
,
G Nenci
9  CHU-Pérouse
,
G Agnelli
9  CHU-Pérouse
,
M d’Addato
10  CHU Bologne
,
H Palumbo
10  CHU Bologne
,
J Bensaid
11  CHU Limoges
,
J Gouffault
12  CHU Rennes
,
P Leborgne
12  CHU Rennes
,
A Le Hellocco
12  CHU Rennes
,
J C Ducreux
13  CHU Roanne
,
G Tempelhoff
13  CHU Roanne
,
E Sala-Planell
14  CHU Barcelotre
,
A Rosendo-Carrera
14  CHU Barcelotre
,
A Torres-Gomez
15  CHU cordoue
,
B Blettery
16  CHU Dijon
,
F Bachmann
17  CHU Lausanne
,
J C Gaux
18  CHU Broussais
,
H Muntlak
19  CHU Saint-Antoine
,
Ch Caulin
20  CHU saint Louis-Lariboisière
,
J F Bergmann
20  CHU saint Louis-Lariboisière
› Author Affiliations
Further Information

Publication History

Received: 10 July 1990

Accepted after revision November 08 November 1990

Publication Date:
24 July 2018 (online)

Summary

The standard treatment of deep vein thrombosis is given by continuous intravenous infusion of unfractionated heparin. This entails hospitalisation, nursing care, immobility and repeated laboratory tests (e.g. activated partial thromboplastin time [APTT], platelet count). In addition approximately 10% of patients suffer major haemorrhages. The potential advantages of a low molecular weight heparin (CY 216) given subcutaneously were explored in a randomised trial with blind quantitative evaluation of venograms. The study included 166 patients and both “therapeutic efficacy” and “intention to-treat” analyses showed that subcutaneous CY 216 in fixed doses based only on body weight was more effective on the Arnesen and Marder phlebographic scores than continuous i. v. standard heparin with daily dose adjustment according to results of coagulation tests. There was no increase in the risks of pulmonary embolism, haemorrhage or clot extension.